Xbrane Refiles Ranibizumab With US FDA

Firm Is Eyeing H1 2024 Approval For US Biosimilar Rival To Lucentis

 
• By Dave Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
Xbrane’s ranibizumab filing is once again with the FDA • Source: Alamy

More from Biosimilars

More from Products